Picoplatin
Names | |
---|---|
IUPAC name
azane; 2-methylpyridine; platinum(2+); dichloride
| |
Identifiers | |
3D model (
JSmol ) |
|
ChemSpider | |
ECHA InfoCard
|
100.205.233 |
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C6H10Cl2N2Pt | |
Molar mass | 376.14 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Picoplatin is a
tumors.[1]
In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.
References
- PMID 20593091.
- ^ Picoplatin Clinical Results, Poniard Pharmaceuticals
- ^ Poniard shares crash on Phase III picoplatin failure, fiercebiotech.com, November 16, 2009
- ^ http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009